Is Farxiga a Semaglutide? Two Very Different Medicines Explained

Step 1: Understanding what Farxiga actually is

Farxiga is the brand name for dapagliflozin, made by AstraZeneca. It belongs to a class called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors) which work in the kidneys by blocking the reabsorption of glucose back into the bloodstream, causing excess glucose to be excreted in urine. That mechanism reduces blood sugar, lowers blood pressure modestly, and can lead to some weight loss over time, typically in the range of 2–4 kg in clinical trials, largely because the body sheds calories through urine.

In the UK, Farxiga holds licences for type 2 diabetes, chronic kidney disease and heart failure with reduced ejection fraction. It is not licensed for weight management, and it is not prescribed for that purpose. If you have seen it mentioned alongside weight-loss medicines, the overlap is informal observation rather than a licensed indication.

A question our prescribers hear most weeks is whether medicines that produce some incidental weight loss (Farxiga among them) can be used as an alternative to dedicated weight-management treatments. The honest answer is that they are prescribed for specific conditions, assessed against specific criteria, and the weight change is a by-product, not the goal.

Step 2: What semaglutide is and how its mechanism differs

Semaglutide mimics a gut hormone called GLP-1 (glucagon-like peptide-1) that is released after eating. By activating GLP-1 receptors in the brain and gut, it reduces appetite, slows the rate at which the stomach empties, and increases the feeling of fullness after smaller amounts of food. That is a fundamentally different target from SGLT2 inhibition, the two medicines do not overlap pharmacologically.

In the UK, semaglutide is available for weight management as Wegovy, a once-weekly injection. A newer oral form, Wegovy tablets, received MHRA approval on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK specifically for weight loss. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, in adults without diabetes. Those are not figures produced by incidental weight-loss effects, semaglutide's entire licensed purpose in Wegovy is weight management.

If you want to read a broader overview of how semaglutide works and what the current evidence covers, the semaglutide overview on our site is a useful starting point, and you can also explore the detail behind semaglutide 1 mg dosing or read about how semaglutide 2 mg fits into the treatment journey.

Step 3: Licensed uses and eligibility side by side

Farxiga is prescribed when someone has a confirmed diagnosis of type 2 diabetes, chronic kidney disease meeting specific criteria, or heart failure. A GP or specialist makes that call based on clinical need. It is not something a person chooses for weight loss, and no UK prescriber would issue it with weight loss as the primary aim.

Wegovy (semaglutide) is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The NHS pages on semaglutide set out the clinical picture clearly, including what the prescriber needs to consider before recommending it.

The practical upshot: if your interest is in a licensed weight-management medicine, Farxiga is not the route. The medicines designed for that purpose in the UK are semaglutide (Wegovy) and tirzepatide (Mounjaro). You can explore weight-loss treatment options at nume if you want to understand how private access to these medicines works.

Step 4: What to do if you are researching weight-loss options

It is worth being clear about one thing: the fact that a medicine can reduce body weight as a side effect does not make it a weight-loss medicine. Farxiga, metformin and several other medicines produce modest weight changes in some patients, but they are prescribed for specific conditions and monitored against those conditions' outcomes. Using them off-label for weight loss is not appropriate clinical practice.

If you are considering a licensed weight-management medicine in the UK, semaglutide (Wegovy) and tirzepatide are the two options with MHRA approval for that purpose. Both are prescription-only, which means a prescriber needs to assess whether they suit your health history before any treatment is issued. Understanding what Wegovy costs privately can help you plan, though the consultation itself at nume is free. For a closer look at how the injection and oral forms compare, the Wegovy equivalent page covers the landscape.

The clearest next step, if you think you might be eligible, is to speak with a clinician who can assess your situation properly. At nume, that means a GPhC-registered Independent Prescriber reads your consultation the same day, not software, not a waiting room. Speak to our prescribers by starting your free consultation.